NASDAQ:IBB - iShares Nasdaq Biotechnology ETF Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$109.73 +1.08 (+0.99 %)
(As of 01/18/2019 04:48 AM ET)
Previous Close$108.65
Today's Range$108.00 - $110.52
52-Week Range$89.01 - $122.97
Volume1.24 million shs
Average Volume2.29 million shs
Market Capitalization$8.26 billion
P/E RatioN/A
Dividend Yield0.17%
Beta1.39
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Receive IBB News and Ratings via Email

Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer BlackRock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$8.95 billion
Average Daily Volume$2.98 million
Discount/Premium1.40%

ETF Expenses

Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)
Currency Exposure of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)
Sector Exposure of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)
Industry Exposure of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Frequently Asked Questions

What is iShares Nasdaq Biotechnology ETF's stock symbol?

iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."

How often does iShares Nasdaq Biotechnology ETF pay dividends? What is the dividend yield for iShares Nasdaq Biotechnology ETF?

iShares Nasdaq Biotechnology ETF announced a quarterly dividend on Thursday, September 27th. Investors of record on Thursday, September 27th will be paid a dividend of $0.0324 per share on Tuesday, October 2nd. This represents a $0.13 dividend on an annualized basis and a dividend yield of 0.12%. The ex-dividend date of this dividend is Wednesday, September 26th. View iShares Nasdaq Biotechnology ETF's Dividend History.

When did iShares Nasdaq Biotechnology ETF's stock split? How did iShares Nasdaq Biotechnology ETF's stock split work?

iShares Nasdaq Biotechnology ETF's stock split on the morning of Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were distributed to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.

Has iShares Nasdaq Biotechnology ETF been receiving favorable news coverage?

News articles about IBB stock have been trending neutral on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. iShares Nasdaq Biotechnology ETF earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the financial services provider a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.

Who are some of iShares Nasdaq Biotechnology ETF's key competitors?

Who are iShares Nasdaq Biotechnology ETF's key executives?

iShares Nasdaq Biotechnology ETF's management team includes the folowing people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
  • Michael Arthur Latham, President, Trustee
  • Jack Gee, Chief Financial Officer, Treasurer
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • , Bio & Compensation - 
  • Amy Schioldager, Executive Vice President
  • Ira P. Shapiro, Vice President, Chief Legal Officer
  • Matt Tucker, Vice President
  • , Bio & Compensation - 
  • Eilleen M. Clavere, Secretary
  • Cecilia H. Herbert, Independent Trustee
  • Charles A. Hurty, Independent Trustee

Who are iShares Nasdaq Biotechnology ETF's major shareholders?

iShares Nasdaq Biotechnology ETF's stock is owned by a number of of retail and institutional investors. Top institutional investors include Ferguson Wellman Capital Management Inc. (0.11%), Patriot Wealth Management Inc. (0.09%), Neville Rodie & Shaw Inc. (0.08%), Appleton Partners Inc. MA (0.07%), Edge Wealth Management LLC (0.07%) and Greystone Investment Management LLC (0.06%).

Which institutional investors are selling iShares Nasdaq Biotechnology ETF stock?

IBB stock was sold by a variety of institutional investors in the last quarter, including Vigilant Capital Management LLC, Steward Partners Investment Advisory LLC, Thomasville National Bank, Blue Fin Capital Inc., Carroll Financial Associates Inc., Patriot Wealth Management Inc., Chesley Taft & Associates LLC and Greystone Investment Management LLC.

Which institutional investors are buying iShares Nasdaq Biotechnology ETF stock?

IBB stock was purchased by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Edge Wealth Management LLC, Virtu Financial LLC, Simplex Trading LLC, Bainco International Investors, MinichMacGregor Wealth Management LLC, Lourd Capital LLC and Private Trust Co. NA.

How do I buy shares of iShares Nasdaq Biotechnology ETF?

Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iShares Nasdaq Biotechnology ETF's stock price today?

One share of IBB stock can currently be purchased for approximately $109.73.

How big of a company is iShares Nasdaq Biotechnology ETF?

iShares Nasdaq Biotechnology ETF has a market capitalization of $8.26 billion.


MarketBeat Community Rating for iShares Nasdaq Biotechnology ETF (NASDAQ IBB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about iShares Nasdaq Biotechnology ETF and other stocks. Vote "Outperform" if you believe IBB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: Net Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel